The Motley Fool
17 Oct 2026, 10:15 UTC · 1h ago
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
Impact · against what's priced in
The updated guidance and revenue beats are largely neutral as they confirm the 6% growth trajectory the market already assumes. However, the MedTech revenue miss and the potential spinoff of DePuy Synthes introduce new risks to the growth acceleration the stock requires to reach its higher valuation targets.
- JNJ+0.00
Already priced in
- The price assumes
The raised 2026 revenue guidance of $100.3–$101.3 billion and adjusted EPS of $11.45–$11.65
